ArticleJournal, genetic engineering & biotechnology2026
Computational design and molecular characterization of a multi-epitope peptide vaccine targeting pancreatic cancer.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a major global health burden, characterized by high mortality rates. Immunotherapy-based strategies have shown promise in combating malignant diseases such as PC. Among these, cancer vaccines are gaining considerable interest as one of the most effective immunotherapeutic approaches. Therefore, in this study, we aimed to develop an effective peptide-based vaccine against PC via immunoinformatic techniques. To construct the vaccine, antigenic proteins associated with PC, including ITGA2, LMAC2, BMPR2, ZFP91, and S100A16, were selected. The predicted epitopes were assembled using proper linkers, and to improve immunogenicity, PADRE and β-defensin 2 sequences were incorporated into the final construct. Further analysis validated the chimeric structure as potentially antigenic, non-allergenic, non-toxic, and soluble. The integrity of its secondary and tertiary structures was also confirmed. Additionally, molecular docking and dynamics simulation of TLR4 demonstrate that the vaccine-receptor complex is structurally stable. The immune simulation results further indicated the vaccines' ability to induce strong cellular and humoral responses. Codon optimization and in silico cloning into an Escherichia coli expression system were also successfully performed. Based on our findings, the proposed vaccine shows promise for targeting PC, warranting further experimental validation in animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.